Senator Thom Tillis has been busy. He has proposed a new act to clarify patent eligibility doctrine in the United States. This is definitely a relatively broad vision of patent eligibility. Some work on the pricing side of pharmaceuticals/biologics would be helpful if this gets passed. I am wondering if this may get tacked on to another piece of legislation—the timing is interesting. The Press Release states: U.S. Senator Thom Tillis (R-NC) introduced the Patent Eligibility Restoration Act of 2022, legislation that will restore patent eligibility to important inventions across many fields, while also resolving legitimate concerns over the patenting of…
Want to view the entire article? Click here: Senator Tillis’ New Proposed Patent Eligible Subject Matter Legislation
The article was originally posted on IP Finance.
Each article is copyrighted to its original authors. We do not own any rights to the news or the images used. Whilst every care is taken to ensure that the news posts published are accurate, we cannot guarantee the authenticity of the news article on every occasion. There’s no copyright infringement intended. The news is for informational purposes only and does not provide legal advice.